COMBINING SGLT2 INHIBITORS AND FINERENONE IN CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME: A CLINICAL UPDATE
Background Patients with chronic kidney disease (CKD), particularly those with type 2 diabetes (T2D) and albuminuria, remain at substantial risk of kidney disease progression and cardiovascular complications despite established therapy. SGLT2 inhibitors and finerenone act through distinct and potentially complementary...